Monthly Archives: September 2018

Stem Cell Research Program – Grants – portal.ct.gov

Posted: September 24, 2018 at 1:44 pm

Connecticut Stem Cell Research Grants-in-Aid Program

The Connecticut Stem Cell Research Grants-in-Aid Program was established by the Connecticut General Assembly in June 2005 when it passed Connecticut General Statutes 19a-32d through 19a-32g. This legislation appropriates $20 million dollars to support embryonic and human adult stem cell research through June 30, 2007. In addition, for each of the fiscal years ending June 30, 2008 through June 30, 2015, the legislation specifies that an additional $10 million dollars should be disbursed to support additional research. In total, at least $100 million in public support will be available over the next ten years for stem cell research.

Lay Summary Example

Below is an example of a lay summary excerpt from a technical report required of all grantees that meets the expectations of the Stem Cell Research Advisory Committee:

5. Detailed lay language summary:

There is great promise in embryonic stem cell-based therapies to treat a variety of neurological disorders. It is key that we understand how the transplanted cells may interact with the host brain to guarantee the safety of this approach. We observe that robust transplants of embryonic stem cell-derived neural progenitors in the hippocampus are richly vascularized, associated with multiple blood vessels. In addition, the transplanted cells can migrate on these blood vessels some distance away from the initial transplant site. We are now studying how interactions with the blood vessels may nurture the transplant and support its successful integration into the host. We are also examining the factors that might promote or inhibit the migration of transplanted cells on the surface of existing blood vessels. This interaction could be used to target grafted cells to a specific site. Alternatively this could be a dangerous process we would like to block, as it could lead to cells present in undesirable places.

Significance of recent findings: When embryonic stem cell-derived neural progenitors are transplanted to the central nervous system, the general expectation is that they will remain where transplanted, or perhaps migrate short distances. Our observation that these cells can migrate on blood vessels long distances sets up a red flag: cells may well end up a great distance from where they were intended to be. By understanding the molecular basis for this migration, we hope to be able to control it, specifically inhibit it when the desire is to keep a transplant in place. Alternatively, it may be desirable to use this blood vessel highway to target cells to specific distant sites.

Frequently Asked Questions

How did Connecticuts Stem Cell Research Program come about?

The Connecticut Stem Cell Research Grant Project is the direct result of legislation passed by the General Assembly in 2005 (Connecticut General Statutes 19a-32d through 19a-32g.). This legislation provides public funding in support of stem cell research on embryonic and human adult stem cells. This legislation also bans the cloning of human beings in Connecticut.

Back to Questions

What kinds of research will be eligible for funding?

The Stem Cell Research Fund supports embryonic and human adult stem cell research, including basic research to determine the properties of stem cells.

Back to Questions

Where is the money coming from for this research?

Stem cell research fundscome from the Stem Cell Research Fund. This Fund will receive a total of $100 million dollars of state money over ten years. The General Assembly had set aside $20 million of state money for the purpose of stem cell research through June 2007. An additional $10 million dollars a year over the subsequent eight years will come from the Connecticut Tobacco Settlement Fund. The Stem Cell Research Fund may also contain any funds received from any public or private contributions, gifts, grants, donations or bequests.

Back to Questions

Who oversees the Stem Cell Research Fund?

The Commissioner of the State Department of Public Health (DPH) may make grants-in-aid from the fund. The Connecticut Stem Cell Research Advisory Committee (Advisory Committee), a legislatively appointed committee established by Connecticut General Statutes 19a-32d through 19a-32g, directs the Commissioner with respect to the awarding of grants-in-aid, and develops the stem cell research application process. The Stem Cell Research Advisory Committee is also required to keep the Governor and the General Assembly apprised of the current status of stem cell research in Connecticut through annual reports commencing June 2007.

The legislation further established a Connecticut Stem Cell Research Peer Review Committee (Peer Review Committee) to review all applications with respect to the scientific and ethical meritsand to make recommendations to the Advisory Committee and the Commissioner of DPH.

Back to Questions

How are the members of the Stem Cell Research Advisory Committee determined?

The Stem Cell Research Advisory Committee is made up of 17 members. By statute, the Advisory Committee is chaired by the Commissioner of the Connecticut Department of Public Health (DPH). Other members of the committee are appointed by the Governor and by various leaders of the General Assembly from the fields of stem cell research, stem cell investigation, bioethics, embryology, genetics, cellular biology and business. Committee members commit to a two-year or four-year term of service.

Back to Questions

Who evaluates the merits of the grant applications and decides how the grants are distributed?

The Stem Cell Research Peer Review Committee reviews all grant applications for scientific and ethical merit, guided by the National Academies Guidelines for Human Embryonic Stem Cell Research. The Stem Cell Research Peer Review Committee makes its recommendations on grants to the Stem Cell Research Advisory Committee for consideration. The members of the Stem Cell Peer Review Committee must have demonstrated and practical knowledge, understanding and experience of the ethical and scientificimplications of embryonic and adult stem cell research. The DPH Commissioner appoints all committee members for either two or four-year terms. The Stem Cell Research Advisory Committee directs the Commissioner of the Department of Public Health with respect to the awarding of grants-in-aid.

Back to Questions

Who may apply for the stem cell research grants?

Any non-profit, tax-exempt academic institution of higher education, any hospital that conducts biomedical research or any entity that conducts biomedical research or embryonic or human adult stem cell research may apply for grants from the Connecticut Stem Cell Research Fund.

Back to Questions

What efforts are being made to assure the people of the state of Connecticut that all committee dealings and any research are ethically conducted?

The State of Connecticut is committed to implementing the Stem Cell Research Program according to the highest ethical and scientific standards, and committed to conducting all business activities in a transparent and consumer friendly manner. Meetings of the committee where decisions are being made will comply with Freedom of Information Act requirements for public meetings and public records. Proceedings of all scheduled meetings of the Advisory Board will be transcribed and made available to the public, and when possible, meetings will be televised via local public access television.

Members of the Stem Cell Research Advisory Committee are considered to be public officials and are subject to state ethics laws, which require full accountability and transparency. Both the Peer Review and Advisory Committees are responsible for overseeing the standards of research funded from this grant program. Reports on scientific progress are required of grant recipients. Annual financial disclosures are required for all members of the Stem Cell Research Advisory Committee.

Back to Questions

Who else is involved with overseeing this project?

The State of Connecticut Department of Public Health, working in conjunction with the legislatively mandated Advisory and Peer Review Committees, is responsible for the overall implementation of the stem cell legislation.Withinthe DPH, the Office of Research and Development is the organizational unit tasked with managing the stem cell research project components.

In addition, the stem cell legislation names Connecticut Innovations as the administrative staff of the Stem Cell Research Advisory Committee, assisting the Advisory Committee in developing and implementing the application process, including application reviews and execution of agreements.

Back to Questions

What is the timeline for the application process?

The Advisory Committee developed and issued the first Request for Proposals on May 10, 2006. As of the July 10, 2006 deadline, 70 applications for public funding were received. Applications were made available for peer review on August 4, 2006.On November 21, 2006, the Stem Cell Research Advisory Committee awarded almost $19.8 million for 21 stem cell research proposals.

The second Request for Proposals was issued on July 25, 2007. As of the November 1, 2007 deadline, 94 applications for public funding were received. The Peer Review Committee completed their review and reported by teleconference on March 5, 2008. On April 1, 2008, the SCRAC awarded $9.84 million for 22 stem cell research projects.

The third Request for Proposals was issued on September 24, 2008. As of the December 8, 2008 deadline, 77 applications for public funding were received. The Peer Review Committee completed their review and reported by teleconference on March 17, 2009. On March 31, 2009, the SCRAC awarded $9.8 million for 24 stem cell research projects.

Back to Questions

Which grant applications received funding in 2006?

An Integrated Approach to Neural Differentiation of Human Embryonic Stem Cells, Yale University, Michael P. Snyder, Principal Investigator, $3,815,476.72

Directing hES Derived Progenitor Cells into Musculoskeletal Lineages, University of Connecticut Health Center and University of Connecticut, David W. Rowe, M. D., Principal Investigator, $3,520,000

Human Embryonic Stem Cell Core Facility at Yale Stem Cell Center, Yale University, Haifan Lin, Principal Investigator, $2,500,000

Human ES Cell Core At University of Connecticut and Wesleyan University, University of Connecticut Health Center, Ren-He Xu, Principal Investigator, $2,500,000

DsRNA and Epigenetic Regulation in Embryonic Stem Cells, University of Connecticut Health Center, Gordon G. Carmichael, $880,000.

Alternative Splicing in Human Embryonic Stem Cells, University of Connecticut Health Center, Brenton R. Graveley, Principal Investigator, $880,000

SMAD4-based ChIP-chip Analysis to Screen Target Genes of BMP and TGF Signaling in Human ES Cells, University of Connecticut Health Center, Ren-He Xu, Principal Investigator, $880,000

Directing Production and Functional Integration of Embryonic Stem Cell-Derived Neural Stem Cells, Wesleyan University, Laura B. Grabel, Principal Investigator, $878,348.24

Role of the Leukemia Gene MKL in Developmental Hematopoiesis Using hES Cells, Yale University, Diane Krause, Principal Investigator, $856,653.72

Migration and Integration of Embryonic Stem Cell Derived Neurons into Cerebral Cortex, University of Connecticut, Joseph LoTurco, Principal Investigator, $561,631.84

Optimizing Axonal Regeneration Using a Polymer Implant Containing hESC-derived Glia, University of Connecticut, Akiko Nishiyama, $529,871.76

Development of Efficient Methods for Reproducible and Inducible Transgene Expression in Human Embryonic Stem Cells, University of Connecticut Health Center, James Li, Principal Investigator, $200,000

Pragmatic Assessment of Epigenetic Drift in Human ES Cell Lines, University of Connecticut, Theodore Rasmussen, Ph.D., Principal Investigator, $200,000

Cell Cycle and Nuclear Reprogramming by Somatic Cell Fusion, University of Connecticut Health Center, Winfried Krueger, Principal Investigator, $200,000

Function of the Fragile X Mental Retardation Protein in Early Human Neural Development, Yale University, Yingqun Joan Huang, Principal Investigator, $200,000

Quantitative Analysis of Molecular Transport and Population Kinetics of Stem Cell Cultivation in a Microfluidic System, University of Connecticut, Tai-His Fan, Principal Investigator, $200,000

Embryonic Stem Cell as a Universal Cancer Vaccine, University of Connecticut Health Center, Bei Liu, Zihai Li, M. D., Principal Investigators, $200,000

Lineage Mapping of Early Human Embryonic Stem Cell Differentiation, University of Connecticut, Craig E. Nelson, $200,000

Directed Isolation of Neuronal Stem Cells from hESC Lines, Yale University School of Medicine, Eleni A. Markakis, Principal Investigator, $184,407

Magnetic Resonance Imaging of Directed Endogenous Neural Progenitor Cell Migration, Yale University School of Medicine, Erik Shapiro, Principal Investigator, $199,975

Generation of Insulin Producing Cells from Human Embryonic Stem Cells, University of Connecticut, Gang Xu, Principal Investigator, $200,000

Back to Questions

Which grant applications received funding in 2008?

Maintaining and Enhancing the Human Embryonic Stem Cell Core at the Yale Stem Cell Center, Yale University Stem Cell Center, New Haven, Haifan Lin, PhD, Principal Investigator, $1,800,000.

Translational Studies in Monkeys of hESCs for Treatment of Parkinsons Disease, Yale University School of Medicine, New Haven, D. Eugene Redmond, Jr., MD, Principal Investigator, $1,120,000.

Production and Validation of Patient-Matched Pluipotent Cells for Improved Cutaneous Repair, University of Connecticut Center of Regenerative Biology, Storrs, Theodore Rasmussen, PhD., Principal Investigator, $634,880.

Directed Differentiation of ESCs into Cochlear Precursors for Transplantation as Treatment of Deafness, University of Connecticut, Storrs, Ben Bahr, PhD, Principal Investigator, $500,000.

Synaptic Replenishment Through Embryonic Stem Cell Derived Neurons in a Transgenic Mouse Model of Alzheimer's Disease, University of Connecticut Health Center, Farmington, Nada Zecevic, MD, PhD, Principal Investigator, $499,813.

Tyrosone Phosphorylation Profiles Associated with Self-Renewal and Differentiation of hESC, University of Connecticut Health Center, Farmington, Bruce Mayer, PhD., Principal Investigator, $450,000.

Directed Differentiation of ESCs into Cochlear Precursors for Transplantation as Treatment of Deafness, University of Connecticut Health Center, Farmington, D. Kent Morest, MD, Principal Investigator, $450,000.

Targeting Lineage Committed Stem Cells to Damaged Intestinal Mucosa, University of Connecticut Health Center, Farmington, Daniel W. Rosenberg, PhD., Principal Investigator, $450,000.

Modeling Motor Neuron Degeneration in Spinal Muscular Atrophy Using hESCs, University of Connecticut Health Center, Farmington, Xuejun Li, PhD., Principal Investigator, $450,000.

Human Embryonic and Adult Stem Cell for Vascular Regeneration, Yale University School of Medicine, New Haven, Laura E. Niklason, MD, PhD, $450,000.

Effect of Hypoxia on Neural Stem Cells and the Function in CAN Repair, Yale University, New Haven, Flora M. Vaccarino, Principal Investigator, $449,771.40.

Wnt Signaling and Cardiomyocyte Differentiation from hESCs, Yale University, New Haven, Dianqing Wu, Principal Investigator, $446,818.50.

Flow Cytometry Core for the Study of hESC, University of Connecticut Health Center, Farmington, Hector Leonardo Aguila, PhD., Principal Investigator, $250,000.

Cortical neuronal protection in spinal cord injury following transplantation of dissociated neurospheres derived from human embryonic stem cells, Yale University School of Medicine, New Haven, Masanori Sasaki, MD, PhD, Principal Investigator, $200,000.

Molecular Control of Pluripotency in Human Embryonic Stem Cell, Yale Stem Cell Center, New Haven, Natalia Ivanova, Principal Investigator, $200,000.

Cytokine-induced Production of Transplantable Hematopoietic Stem Cells from Human ES Cells, University of Connecticut Health Center, Farmington, Laijun Lai, PhD, Principal Investigator, $200,000.

Functional Use of Embryonic Stem Cells for Kidney Repair, Yale University, New Haven, Lloyd G. Cantley, Principal Investigator, $200,000.

VRK-1-mediated Regulation of p53 in the Human ES Cell Cycle, Yale University, New Haven, Valerie Reinke, Principal Investigator, $200,000.

Definitive Hematopoitic Differentiation of hESCs under Feeder-Free and Serum-Free Conditions, Yale University, Caihong Qiu, PhD, Principal Investigator, $200,000.

Differentiation of hESC Lines to Neural Crest Derived Trabecular Meshwork Like Cells Implications in Glaucoma, University of Connecticut Health Center, Farmington, Dharamainder Choudhary, PhD., Principal Investigator, $200,000.

The Role of the piRNA Pathway in Epigenetic Regulation of hESCs, Yale University, New Haven, Qiaoqiao Wang, PhD., Principal Investigator, $200,000.

Early Differentiation Markers in hESCs: Identification and Characterization of Candidates, University of Connecticut Center for Regenerative Biology, Storrs, Mark G. Carter, PhD., Principal Investigator, $200,000.

Regulation hESC-dervied Neural Stem Cells by Notch Signaling, Yale University, New Haven, Joshua Breunig, MD, Principal Investigator, $188,676.

Back to Questions

Which grant applications received funding in 2009?

Continuing and Enhancing the UCONN-Wesleyan Stem Cell Core, University of Connecticut Stem Cell Center, Farmington, Ren-He Xu, MD, PhD, Principal Investigator, $1,900,000.00.

Williams Syndrome Associated TFII-I Factor and Epigenetic Marking-Out in hES and Induced Pluripotent Stem Cells, University of Connecticut Health Center, Farmington, Dashzeveg Bayarsaihan, PhD., Principal Investigator, $500,000.00.

Cellular transplantation of neural progenitors derived from human embryonic stem cells to remyelinate the nonhuman primate spinal cord, Yale University, New Haven, Jeffrey Kocsis, PhD., Principal Investigator, $500,000.00.

Mechanisms of Stem Cell Homing to the Injured Heart, University of Connecticut Health Center, Linda Shapiro, PhD., Principal Investigator, $500,000.00.

Originally posted here:
Stem Cell Research Program - Grants - portal.ct.gov

Posted in Connecticut Stem Cells | Comments Off on Stem Cell Research Program – Grants – portal.ct.gov

PRP vs Stem Cell Injections | Southwest Spine and Pain Center

Posted: September 24, 2018 at 1:43 pm

Platelet rich plasma and stem cell therapy are continuously studied for their regenerative benefit in sports medicine and chronic pain treatment. Insurance companies do not currently reimburse these non-surgical treatments because the long-term effects of them need to be studied longer. However, many physicians offer these life-changing treatments to patients in need of restored function, pain relief, and care for knee, ankle, foot, and shoulder injuries for example.

Southwest Spine and Pain Center is proud to announce that we now offer platelet rich plasma (PRP) injection therapy. Patients are encouraged to talk to their Southwest Spine and Pain physician about this treatment option and how it could benefit their chronic condition. With four locations across Utah, Southwest Spine and Pain Center is better able to provide the best pain treatment to suffering patients.

We often hear PRP injections and stem cell treatment grouped together. For PRP injections, a physician uses the patients own blood to separate platelets in a centrifuge. The platelets are then re-injected into the injured area, releasing growth factors that promote natural tissue healing.

Stem cell therapy is a completely different process of extracting rejuvenating cells. For the procedure, stem cells from either bone marrow or fat tissue used in conjunction with platelets. Stem cells from bone marrow, called autologous mesenchymal, produce cartilage and typically used in treating arthritic conditions and sports injuries. Stem cells from fat tissue are utilized with platelets to heal an osteoarthritic joint, for example, to regrow cartilage.

Remarkable results have come from PRP injections as well as stem cell therapy. Common injuries or conditions that are often improved with these treatments include:

To learn more about PRP injections and if you are a candidate for treatment, contact a Southwest Spine and Pain Center physician today.

If chronic pain is impacting your life, don't wait to schedule an appointment at Southwest Spine and Pain Center. With three locations and growing, the pain management specialists at Southwest Spine and Pain Center are dedicated to helping those who suffer from chronic pain live the life they want to! To schedule an appointment, visit our locations tab!

The advice and information contained in this article is for educational purposes only, and is not intended to replace or counter a physicians advice or judgment. Please always consult your physician before taking any advice learned here or in any other educational medical material.

Southwest Spine and Pain Center, 2014

Medical Marketing Solutions, 2014

See the article here:
PRP vs Stem Cell Injections | Southwest Spine and Pain Center

Posted in Utah Stem Cells | Comments Off on PRP vs Stem Cell Injections | Southwest Spine and Pain Center

Southwest Spine and Sports – Pain Management Doctor Arizona

Posted: September 24, 2018 at 1:40 pm

Disc Treatment Overcomes Lifes Speed Bumps

They might look harmless, but even low-rise speed bumps can do serious damage. Travelling at the 35 mph speed limit near the Ontario (CA) airport one night in 2009, Stephen Cases vehicle hit a poorly marked speed bump. The pain was instantaneous, Case said, and excruciating.Read more

I put too much stress on my shoulders when I was redecorating a house, Melano said. I was removing pictures from the house and had my arms up all day, hammering and hanging. The next day, Melano, 78, decided to work on the library in the house. I was on the last run, picking up one more box of books and it felt like a rubber band broke in my left shoulder. Read more

The original back injury remains a mystery, but add a torn hamstring and any active mom would have to slow down any active mom especially when the back injury resulted in two degenerative discs. For Astrid Corretjer, that meant the end of tennis, rollerblading, paddle boarding, and especially mountain biking.Read more

Walking up and down stairs might not seem exciting. For Carol Kichler, though, climbing and descending stairs without excruciating pain is a daily highlight. Kichler, 73, couldnt walk up or down even two steps without agonizing pain before September, when she received stem cell treatments in her knees.Read more

Eds retirement, and accompanying occasional rounds of golf, were threatened by a bad shoulder. A combination of bursitis and a small tear in the rotator cuff of his right shoulder made golf impossible.Read more

The doctors at Southwest Spine & Sports are board certified by the American Board of Physical Medicine and Rehabilitation with advanced fellowship training in interventional spine care. We specialize in physical medicine, pain management, and comprehensive rehabilitation with one goal in mind restoring quality of life by relieving your pain.

Youll receive expert guidance designed to prevent re-injury and help you stay as active as possible at any age. Together well reduce your pain with innovative nonsurgical solutions that result in a quicker recovery, fewer lost workdays, and enhanced performance.

Who do we treat?

Autologous stem cells, which come from bone marrow aspirate concentrate from a patients own hip bone, are used to treat sports injuries and chronic musculoskeletal conditions. Professional athletes have used stem cells for years now its your turn! If you are a patient with chronic low back pain from degenerative disc disease, joint pain or tendinitis, come in for an evaluation and see if you are a candidate for treatment with one of our regenerative medicine procedures (autologous stem cell concentrate, PRP or Fibrin Disc Sealant). You may also qualify to participate in our ongoing study.

Looking for Regenerative Medicine in Glendale, Phoenix, Scottsdale, or Tempe? Click here or call (480) 860-8998 for a consultation to see how we can help you.

Go here to read the rest:
Southwest Spine and Sports - Pain Management Doctor Arizona

Posted in Arizona Stem Cells | Comments Off on Southwest Spine and Sports – Pain Management Doctor Arizona

Conjoined twins – Wikipedia

Posted: September 20, 2018 at 3:45 am

Conjoined twins are identical twins[1] joined in utero. An extremely rare phenomenon, the occurrence is estimated to range from 1 in 49,000 births to 1 in 189,000 births, with a somewhat higher incidence in Southwest Asia and Africa.[2] Approximately half are stillborn, and an additional one-third die within 24 hours. Most live births are female, with a ratio of 3:1.[2][3]

Two contradicting theories exist to explain the origins of conjoined twins. The more generally accepted theory is fission, in which the fertilized egg splits partially.[4] The other theory, no longer believed to be the basis of conjoined twinning,[4] is fusion, in which a fertilized egg completely separates, but stem cells (which search for similar cells) find similar stem cells on the other twin and fuse the twins together. Conjoined twins share a single common chorion, placenta, and amniotic sac, although these characteristics are not exclusive to conjoined twins, as there are some monozygotic but non-conjoined twins who also share these structures in utero.[5]

The most famous pair of conjoined twins was Chang and Eng Bunker (Thai: -, In-Chan) (18111874), Thai brothers born in Siam, now Thailand. They traveled with P.T. Barnum's circus for many years and were labeled as the Siamese twins. Chang and Eng were joined at the torso by a band of flesh, cartilage, and their fused livers. In modern times, they could have been easily separated.[6] Due to the brothers' fame and the rarity of the condition, the term "Siamese twins" came to be used as a synonym for conjoined twins.[7]

Conjoined twins are typically classified by the point at which their bodies are joined. The most common types of conjoined twins are:

Other, less common types of conjoined twins include:

There are two theories about the development of conjoined twins. The first is that a single fertilized egg does not fully split during the process of forming identical twins. The second theory is that a fusion of two fertilized eggs occurs earlier in development. Although conjoined twinning has not been linked to any environmental or genetic cause, they occur so rarely it has not been possible to draw firm conclusions.

Surgery to separate conjoined twins may range from very easy to very difficult depending on the point of attachment and the internal parts that are shared. Most cases of separation are extremely risky and life-threatening. In many cases, the surgery results in the death of one or both of the twins, particularly if they are joined at the head or share a vital organ. This makes the ethics of surgical separation, where the twins can survive if not separated, contentious. Alice Dreger of Northwestern University found the quality of life of twins who remain conjoined to be higher than is commonly supposed.[11] Lori and George Schappell and Abby and Brittany Hensel are notable examples.

The first record of separating conjoined twins took place in the Byzantine Empire in the 900s. One of the conjoined twins had already died, so surgeons attempted to separate the dead twin from the surviving twin. The result was partly successful as the remaining twin lived for three days after separation. The next case of separating conjoined twins was recorded in 1689 in Germany several centuries later.[12][13] The first recorded successful separation of conjoined twins was performed in 1689 by Johannes Fatio.[14] In 1955, neurosurgeon Harold Voris (1902-1980)[15] and his team at Mercy Hospital in Chicago performed the first successful operation to separate craniopagus twins (conjoined at the head), which resulted in long-term survival for both.[16][17][18] The larger girl was reported in 1963 as developing normally, but the smaller was permanently impaired.[19]

In 1957, Bertram Katz and his surgical team made international medical history performing the world's first successful separation of conjoined twins sharing a vital organ.[20] Omphalopagus twins John Nelson and James Edward Freeman (Johnny and Jimmy) were born in Youngstown, Ohio, on April 27, 1956. The boys shared a liver but had separate hearts and were successfully separated at North Side Hospital in Youngstown, Ohio, by Bertram Katz. The operation was funded by the Ohio Crippled Children's Service Society.[21]

Recent successful separations of conjoined twins include that of the separation of Ganga and Jamuna Shreshta in 2001, who were born in Kathmandu, Nepal, in 2000. The 197-hour surgery on the pair of craniopagus twins was a landmark one which took place in Singapore; the team was led by neurosurgeons Chumpon Chan and Keith Goh.[22] The surgery left Ganga with brain damage and Jamuna unable to walk. Seven years later, Ganga Shrestha died at the Model Hospital in Kathmandu in July 2009, at the age of 8, three days after being admitted for treatment of a severe chest infection.[23]

Infants Rose and Grace ("Mary" and "Jodie") Attard, conjoined twins from Malta, were separated in Great Britain by court order Re A (Children) (Conjoined Twins: Surgical Separation) over the religious objections of their parents, Michaelangelo and Rina Attard. The twins were attached at the lower abdomen and spine. The surgery took place in November, 2000, at St Mary's Hospital in Manchester. The operation was controversial because Rose, the weaker twin, would die as a result of the procedure as her heart and lungs were dependent upon Grace's. However, if the operation had not taken place, it was certain that both twins would die.[24][25] Grace survived to enjoy a normal childhood.[26]

In 2003, two 29-year-old women from Iran, Ladan and Laleh Bijani, who were joined at the head but had separate brains (craniopagus) were surgically separated in Singapore, despite surgeons' warnings that the operation could be fatal to one or both. Their complex case was accepted only because technologically advanced graphical imagery and modelling would allow the medical team to plan the risky surgery. Unfortunately, an undetected major vein hidden from the scans was discovered during the operation.[27] The separation was completed but both women died while still in surgery.

The Moche culture of ancient Peru depicted conjoined twins in their ceramics dating back to 300 CE.[28] Writing around 415 CE, St. Augustine of Hippo, in his book, City of God, refers to a man "double in his upper, but single in his lower half--having two heads, two chests, four hands, but one body and two feet like an ordinary man."[29]

According to Theophanes the Confessor, a Byzantine historian of the 9th century, around 385/386 CE, "in the village of Emmaus in Palestine, "a child was born perfectly normal below the navel but divided above it, so that it had two chests and two heads, each possessing the senses. One would eat and drink but the other did not eat; one would sleep but the other stayed awake. There were times when they played with each other, when both cried and hit each other. They lived for a little over two years. One died while the other lived for another four days and it, too, died."[30]

In Arabia, the twin brothers Hashim ibn Abd Manaf and 'Abd Shams were born with Hashim's leg attached to his twin brother's head. Legend says that their father, Abd Manaf ibn Qusai, separated his conjoined sons with a sword and that some priests believed that the blood that had flowed between them signified wars between their progeny (confrontations did occur between Banu al'Abbas and Banu Ummaya ibn 'Abd Shams in the year 750 AH).[31] The Muslim polymath Ab al-Rayhn al-Brn described conjoined twins in his book Kitab-al-Saidana.[32]

The English twin sisters Mary and Eliza Chulkhurst, who were conjoined at the back (pygopagus), lived from 1100 to 1134 (or 1500 to 1534) and were perhaps the best-known early historical example of conjoined twins. Other early conjoined twins to attain notice were the "Scottish brothers", allegedly of the dicephalus type, essentially two heads sharing the same body (14601488, although the dates vary); the pygopagus Helen and Judith of Szny, Hungary (17011723), who enjoyed a brief career in music before being sent to live in a convent; and Rita and Cristina of Parodi of Sardinia, born in 1829. Rita and Cristina were dicephalus tetrabrachius (one body with four arms) twins and although they died at only eight months of age, they gained much attention as a curiosity when their parents exhibited them in Paris.

Several sets of conjoined twins lived during the nineteenth century and made careers for themselves in the performing arts, though none achieved quite the same level of fame and fortune as Chang and Eng. Most notably, Millie and Christine McCoy (or McKoy), pygopagus twins, were born into slavery in North Carolina in 1851. They were sold to a showman, J.P. Smith, at birth, but were soon kidnapped by a rival showman. The kidnapper fled to England but was thwarted because England had already banned slavery. Smith traveled to England to collect the girls and brought with him their mother, Monimia, from whom they had been separated. He and his wife provided the twins with an education and taught them to speak five languages, play music, and sing. For the rest of the century, the twins enjoyed a successful career as "The Two-Headed Nightingale" and appeared with the Barnum Circus. In 1912, they died of tuberculosis, 17 hours apart.

Giovanni and Giacomo Tocci, from Locana, Italy, were immortalized in Mark Twain's short story "Those Extraordinary Twins" as fictitious twins Angelo and Luigi. The Toccis, born in 1877, were dicephalus tetrabrachius twins, having one body with two legs, two heads, and four arms. From birth they were forced by their parents to perform and never learned to walk, as each twin controlled one leg (in modern times, physical therapy allows twins like the Toccis to learn to walk on their own). They are said to have disliked show business. In 1886, after touring the United States, the twins returned to Europe with their family, where they fell ill. They are believed to have died around this time, though some sources claim they survived until 1940, living in seclusion in Italy.

Link:
Conjoined twins - Wikipedia

Posted in Ohio Stem Cells | Comments Off on Conjoined twins – Wikipedia

The Forever Fix: Gene Therapy and the Boy Who Saved It …

Posted: September 20, 2018 at 3:44 am

In this impressive, meticulously researched study of the exciting new developments in gene therapy, geneticist and journalist Lewis (Human Genetics) looks closely at the history of setbacks plaguing the treatment of rare genetic diseases as well as recent breakthroughs...Yet with each success, as Lewis recounts in this rigorous, energetic work, possibilities in treating HIV infection and dozens of other diseases might be around the next corner. Publisher's Weekly (starred review)

A fascinating account of groundbreaking science and the people who make it possible. Kirkus

Ricki Lewis gives us the inspiring story of gene therapy as told through Corey's eyes--literally. Her book delves into the challenges modern medicine faces--both in its bitter disappointments and great successes--but it goes much deeper than that. With empathy and grace, Lewis shows us the unimaginable strength of parents with sick children and the untiring devotion of the physicians who work to find the forever fix' to save them. But best of all Lewis gives us a story of profound hope. Molly Caldwell Crosby, author of The American Plague: The Untold Story of Yellow Fever, the Epidemic that Shaped Our History and Asleep: The Forgotten Epidemic that Remains One of Medicine's Greatest Mysteries

The Forever Fix is a wonderful story told by one of our most gifted science and medical writers. In the tradition of Siddhartha Mukherjee's The Emperor of All Maladies, Ricki Lewis explains complex biological processes in extremely understandable ways, ultimately providing crucial insights into the modeling of disease and illustrating how gene therapy can treat and even potentially cure the most challenging of our health conditions. Dennis A. Steindler, Ph.D., former Executive Director of the McKnight Brain Institute, University of Florida

Ricki Lewis has written a remarkable book that vividly captures the breathtaking highs and devastating lows of gene therapy over the past decade while giving ample voice to all sides -- the brave patient volunteers, their parents and physicians. The Forever Fix is required reading as we dare to dream of curing a host of genetic diseases. Kevin Davies, Founding editor of Nature Genetics; author of The $1,000 Genome and Cracking the Genome

In 'The Forever Fix,' Ms. Lewis chronicles gene therapy's climb toward the Peak of Inflated Expectations over the course of the 1990s. A geneticist and the author of a widely used textbook, she demonstrates a mastery of the history. The Wall Street Journal

An engaging and accessible look at gene therapy. Times Union

Medical writer Ricki Lewis interweaves science, the history of medical trial and error, and human stories from the death in 1999 of teenager Jesse Gelsinger, from a reaction to gene therapy intended to combat his liver disease, to radical successes in some children with adenosine deaminase deficiency. Nature

Lewis adeptly traverses the highs and lows of gene therapy and explores its past, present, and future through the tales of those who've tested its validity. The Scientist

The rest is here:
The Forever Fix: Gene Therapy and the Boy Who Saved It ...

Posted in Gene therapy | Comments Off on The Forever Fix: Gene Therapy and the Boy Who Saved It …

Cord Blood Storage, NY and NJ | Community Blood Services

Posted: September 20, 2018 at 3:43 am

YOU HAVE A CHOICEThe New Jersey Cord Blood Bank (NJCBB)Our public banking program

Click here for participating hospitals

Call 1 866 SAVCORD (728-2673) for more information

The umbilical cord blood program was established in 1996 to meet the needs of a growing population of cancer patients who became candidates for stem cell transplants after their stem cells were damaged or destroyed during aggressive treatment for cancer or other diseases. Cord blood stem cells are currently being used to treat more than 70 diseases, and may be the treatment of choice in the near future for such diseases as diabetes, heart disease, breast cancer, Alzheimers disease, Parkinsons disease, as well as spinal cord injuries and many other serious diseases.

Parents delivering at participating hospitals can arrange for the safe and painless collection of their babies umbilical cord blood, which is a rich source of stem cells, after their babies are born. Parents can donate their babies cord blood to the NJCBB for use by any child or adult in the U.S. and throughout the world with a life-threatening disease. Stem cell transplants are being used in the treatment of leukemia, lymphoma, Hodgkins disease, sickle cell anemia, cerebral palsy, aplastic anemia and various other cancers, blood diseases, hereditary conditions and immune system disorders. In the future, stem cells may be used to fight heart disease, breast cancer, diabetes, Parkinsons disease, Alzheimers disease, multiple sclerosis, diabetes, AIDS, and a score of other genetic diseases.

Umbilical cord blood may also be saved for future use if needed by that particular child, a sibling or a parent through the family banking program, the Elie Katz Umbilical Cord Blood Program (EKUCBP). Collections are accepted from most regional hospitals. Expectant parents who want further information about the family banking program should call 1 866 SAVCORD (728-2673).

As one of the few banks designated to process and store umbilical cord blood for both public and private use, Community Blood Services maintains high industry standards. Its rigorous quality control standards are assessed and confirmed by regulatory agencies such as the U.S. Food and Drug Administration (FDA), the AABB (formerly known as American Association of Blood Banks), and state health offices. Community Blood Services is a member of National Cord Blood Inventory (NCBI) the National Marrow Donor Program (NMDP); accredited by AABB and the American Society of Histocompatibility and Immunogenetics (ASHI); registered with the U.S. Food and Drug Administration (FDA); and licensed by New Jersey, New York, Maryland, and California State.

A staff of highly experienced health professionals and technicians, working under the guidance and expertise of Community Blood Services Scientific/Medical Advisory Panel of industry leaders, physicians, researchers, and parent advocates, offers both technical skill and unparalleled leadership. This unique combination of talents ensures that our laboratory remains on the cutting-edge of new cord blood advances, while it guarantees the safety, integrity, and viability of your clients babys cord blood unit.

Processing of Umbilical Cord Blood (UCB) units at Community Blood Services ensures that your babys cells are rapidly and precisely extracted from the cord blood unit, and that they remain healthy and contamination-free. Following collection at time of delivery, your babys cord blood unit is immediately shipped under highly controlled conditions to Community Blood Services cord blood laboratory, which is equipped with the most advanced processing and storage technologies. The cord bloods stem cells are processed the same day your babys unit is received in our laboratory. Samples are tested for cell viability, total nucleated cell count (TNC), sterility, infectious disease markers, number of stem cells, and blood type.

Family banked (private use) UCB units are processed via the manual advanced separation method. Occasionally, family banked units may be collected below or above optimal volume. Although the manual process is more labor intensive, the chief advantage is that better cell recovery results have been found during manual processing tests.

Publicly banked UCB units are processed using the automated Sepax cell processing system. Sepax Cell processing technology has received 510K clearance by the US Food and Drug Administration.

As one of the few banks designated to process and store umbilical cord blood for both public and private use, Community Blood Services maintains high industry standards. All processing and testing is performed following rigorous quality control standards set by state and federal regulatory agencies.

Maintaining the viability and health of your babys stem cells throughout processing requires careful lowering of the temperature prior to freezing and storage. Our laboratorys state-of-the-art automated mixing and cooling device, Coolmix, offers a controlled freezing process that ensures the cells integrity and future viability. Once the stem cells are brought to the optimum temperature, they are placed in a storage cartridge and then into a storage tank. You can be assured your babys cord blood unit will be kept at the correct temperature at all times thanks to our back-up generators and battery system. Public and private family units are stored separately in freezers located in specifically designated storage areas.

Detailed reports are provided throughout the processing and testing of your babys cord blood unit. These include a receipt report, a processing report and a final report that details all of the pertinent information regarding the stored unit.

Click here to display our Scientific/Medical Advisory Panel.

Click here to display the Parents Guide to Cord Blood website.

For more information on how to obtain your cord blood collector training and certification from Community Blood Services Click here.

Follow this link:
Cord Blood Storage, NY and NJ | Community Blood Services

Posted in New Jersey Stem Cells | Comments Off on Cord Blood Storage, NY and NJ | Community Blood Services

Stem Cell Florence South Carolina 29506

Posted: September 20, 2018 at 3:42 am

Stem cell treatment has actually ended up being a popular argument in the international medical scene. This highly questionable treatment has received mixed viewpoints from numerous stakeholders in the healthcare market and has likewise drawn in the attention of politicians, religious leaders and the general population at large. Stem cell treatment is thought about an advanced treatment for people suffering from a large range of degenerative conditions. Some typical questions regarding this therapy are answered below.

Stem cells can be described as blank state or non-specialized cells that have the ability to become specialized cells in the body such as bone, muscle, nerve or organ cells. This suggests that these special cells can be used to regrow or establish a vast array of broken cells and tissues in the body. Stem cell treatment is therefore a treatment that targets at attaining tissue regrowth and can be used to cure health conditions and health problems such as osteoarthritis, degenerative disc disease, spine injury, muscular degeneration, motor neuron illness, ALS, Parkinsons, heart disease and many more.

Stem cells can be extracted from a young embryo after conception. These stem cells are frequently referred to as embryonic stem cells. After the stem cells are drawn out from the embryo, the embryo is terminated. This is basically among the significant causes of controversy in the field of stem cell studio. Lots of people suggest that termination of an embryo is dishonest and unacceptable.

Stem cells can still be gotten through other means as they can be discovered in the blood, bone marrow and umbilical cords of adult human beings. Normal body cells can also be reverse-engineered to become stem cells that have limited abilities.

Being a treatment that is still under research, stem cell therapy has not been totally accepted as a feasible treatment alternative for the above pointed out health conditions and health problems. A lot of research is presently being carried out by researchers and medical specialists in numerous parts of the world to make this treatment practical and reliable. There are nevertheless various restrictions imposed by federal governments on research including embryonic stem cells.

Presently, there have not been many case studies carried out for this form of treatment. Nevertheless, with the few case studies that have been conducted, among the major concerns that has been raised is the boost in a clients danger of establishing cancer. Cancer is caused by the fast reproduction of cells that have a tendency not to die so quickly. Stem cells have actually been related to similar growth elements that might cause development of growths and other malignant cells in clients.

New studio has however shown pledge as scientists aim at establishing stem cells that do not form into tumors in later treatment phases. These stem cells can therefore efficiently transform into other types of specialized cells. This therapy is therefore worth researching into as lots of clients can take advantage of this advanced treatment.

Need a stem cell therapy close to Florence SC 29506

55

Main address:South Carolina

Read the original post:
Stem Cell Florence South Carolina 29506

Posted in South Carolina Stem Cells | Comments Off on Stem Cell Florence South Carolina 29506

Stem Cells – MedicineNet

Posted: September 18, 2018 at 8:44 pm

Stem cell facts

What are stem cells?

Stem cells are cells that have the potential to develop into many different or specialized cell types. Stem cells can be thought of as primitive, "unspecialized" cells that are able to divide and become specialized cells of the body such as liver cells, muscle cells, blood cells, and other cells with specific functions. Stem cells are referred to as "undifferentiated" cells because they have not yet committed to a developmental path that will form a specific tissue or organ. The process of changing into a specific cell type is known as differentiation. In some areas of the body, stem cells divide regularly to renew and repair the existing tissue. The bone marrow and gastrointestinal tract are examples of areas in which stem cells function to renew and repair tissue.

The best and most readily understood example of a stem cell in humans is that of the fertilized egg, or zygote. A zygote is a single cell that is formed by the union of a sperm and ovum. The sperm and the ovum each carry half of the genetic material required to form a new individual. Once that single cell or zygote starts dividing, it is known as an embryo. One cell becomes two, two become four, four become eight, eight become sixteen, and so on, doubling rapidly until it ultimately grows into an entire sophisticated organism composed of many different kinds of specialized cells. That organism, a person, is an immensely complicated structure consisting of many, many, billions of cells with functions as diverse as those of your eyes, your heart, your immune system, the color of your skin, your brain, etc. All of the specialized cells that make up these body systems are descendants of the original zygote, a stem cell with the potential to ultimately develop into all kinds of body cells. The cells of a zygote are totipotent, meaning that they have the capacity to develop into any type of cell in the body.

The process by which stem cells commit to become differentiated, or specialized, cells is complex and involves the regulation of gene expression. Research is ongoing to further understand the molecular events and controls necessary for stem cells to become specialized cell types.

Stem Cells:One of the human body's master cells, with the ability to grow into any one of the body's more than 200 cell types.

All stem cells are unspecialized (undifferentiated) cells that are characteristically of the same family type (lineage). They retain the ability to divide throughout life and give rise to cells that can become highly specialized and take the place of cells that die or are lost.

Stem cells contribute to the body's ability to renew and repair its tissues. Unlike mature cells, which are permanently committed to their fate, stem cells can both renew themselves as well as create new cells of whatever tissue they belong to (and other tissues).

Why are stem cells important?

Stem cells represent an exciting area in medicine because of their potential to regenerate and repair damaged tissue. Some current therapies, such as bone marrow transplantation, already make use of stem cells and their potential for regeneration of damaged tissues. Other therapies that are under investigation involve transplanting stem cells into a damaged body part and directing them to grow and differentiate into healthy tissue.

Embryonic stem cells

During the early stages of embryonic development the cells remain relatively undifferentiated (immature) and appear to possess the ability to become, or differentiate, into almost any tissue within the body. For example, cells taken from one section of an embryo that might have become part of the eye can be transferred into another section of the embryo and could develop into blood, muscle, nerve, or liver cells.

Cells in the early embryonic stage are totipotent (see above) and can differentiate to become any type of body cell. After about seven days, the zygote forms a structure known as a blastocyst, which contains a mass of cells that eventually become the fetus, as well as trophoblastic tissue that eventually becomes the placenta. If cells are taken from the blastocyst at this stage, they are known as pluripotent, meaning that they have the capacity to become many different types of human cells. Cells at this stage are often referred to as blastocyst embryonic stem cells. When any type of embryonic stem cells is grown in culture in the laboratory, they can divide and grow indefinitely. These cells are then known as embryonic stem cell lines.

Fetal stem cells

The embryo is referred to as a fetus after the eighth week of development. The fetus contains stem cells that are pluripotent and eventually develop into the different body tissues in the fetus.

Adult stem cells

Adult stem cells are present in all humans in small numbers. The adult stem cell is one of the class of cells that we have been able to manipulate quite effectively in the bone marrow transplant arena over the past 30 years. These are stem cells that are largely tissue-specific in their location. Rather than typically giving rise to all of the cells of the body, these cells are capable of giving rise only to a few types of cells that develop into a specific tissue or organ. They are therefore known as multipotent stem cells. Adult stem cells are sometimes referred to as somatic stem cells.

The best characterized example of an adult stem cell is the blood stem cell (the hematopoietic stem cell). When we refer to a bone marrow transplant, a stem cell transplant, or a blood transplant, the cell being transplanted is the hematopoietic stem cell, or blood stem cell. This cell is a very rare cell that is found primarily within the bone marrow of the adult.

One of the exciting discoveries of the last years has been the overturning of a long-held scientific belief that an adult stem cell was a completely committed stem cell. It was previously believed that a hematopoietic, or blood-forming stem cell, could only create other blood cells and could never become another type of stem cell. There is now evidence that some of these apparently committed adult stem cells are able to change direction to become a stem cell in a different organ. For example, there are some models of bone marrow transplantation in rats with damaged livers in which the liver partially re-grows with cells that are derived from transplanted bone marrow. Similar studies can be done showing that many different cell types can be derived from each other. It appears that heart cells can be grown from bone marrow stem cells, that bone marrow cells can be grown from stem cells derived from muscle, and that brain stem cells can turn into many types of cells.

Peripheral blood stem cells

Most blood stem cells are present in the bone marrow, but a few are present in the bloodstream. This means that these so-called peripheral blood stem cells (PBSCs) can be isolated from a drawn blood sample. The blood stem cell is capable of giving rise to a very large number of very different cells that make up the blood and immune system, including red blood cells, platelets, granulocytes, and lymphocytes.

All of these very different cells with very different functions are derived from a common, ancestral, committed blood-forming (hematopoietic), stem cell.

Umbilical cord stem cells

Blood from the umbilical cord contains some stem cells that are genetically identical to the newborn. Like adult stem cells, these are multipotent stem cells that are able to differentiate into certain, but not all, cell types. For this reason, umbilical cord blood is often banked, or stored, for possible future use should the individual require stem cell therapy.

Induced pluripotent stem cells

Induced pluripotent stem cells (iPSCs) were first created from human cells in 2007. These are adult cells that have been genetically converted to an embryonic stem celllike state. In animal studies, iPSCs have been shown to possess characteristics of pluripotent stem cells. Human iPSCs can differentiate and become multiple different fetal cell types. iPSCs are valuable aids in the study of disease development and drug treatment, and they may have future uses in transplantation medicine. Further research is needed regarding the development and use of these cells.

Why is there controversy surrounding the use of stem cells?

Embryonic stem cells and embryonic stem cell lines have received much public attention concerning the ethics of their use or non-use. Clearly, there is hope that a large number of treatment advances could occur as a result of growing and differentiating these embryonic stem cells in the laboratory. It is equally clear that each embryonic stem cell line has been derived from a human embryo created through in-vitro fertilization (IVF) or through cloning technologies, with all the attendant ethical, religious, and philosophical problems, depending upon one's perspective.

What are some stem cell therapies that are currently available?

Routine use of stem cells in therapy has been limited to blood-forming stem cells (hematopoietic stem cells) derived from bone marrow, peripheral blood, or umbilical cord blood. Bone marrow transplantation is the most familiar form of stem cell therapy and the only instance of stem cell therapy in common use. It is used to treat cancers of the blood cells (leukemias) and other disorders of the blood and bone marrow.

In bone marrow transplantation, the patient's existing white blood cells and bone marrow are destroyed using chemotherapy and radiation therapy. Then, a sample of bone marrow (containing stem cells) from a healthy, immunologically matched donor is injected into the patient. The transplanted stem cells populate the recipient's bone marrow and begin producing new, healthy blood cells.

Umbilical cord blood stem cells and peripheral blood stem cells can also be used instead of bone marrow samples to repopulate the bone marrow in the process of bone marrow transplantation.

In 2009, the California-based company Geron received clearance from the U. S. Food and Drug Administration (FDA) to begin the first human clinical trial of cells derived from human embryonic stem cells in the treatment of patients with acute spinal cord injury.

What are experimental treatments using stem cells and possible future directions for stem cell therapy?

Stem cell therapy is an exciting and active field of biomedical research. Scientists and physicians are investigating the use of stem cells in therapies to treat a wide variety of diseases and injuries. For a stem cell therapy to be successful, a number of factors must be considered. The appropriate type of stem cell must be chosen, and the stem cells must be matched to the recipient so that they are not destroyed by the recipient's immune system. It is also critical to develop a system for effective delivery of the stem cells to the desired location in the body. Finally, devising methods to "switch on" and control the differentiation of stem cells and ensure that they develop into the desired tissue type is critical for the success of any stem cell therapy.

Researchers are currently examining the use of stem cells to regenerate damaged or diseased tissue in many conditions, including those listed below.

References

REFERENCE:

"Stem Cell Information." National Institutes of Health.

Read the original post:
Stem Cells - MedicineNet

Posted in Stem Cells | Comments Off on Stem Cells – MedicineNet

How Does Gene Therapy Work? – YouTube

Posted: September 18, 2018 at 8:41 pm

Scientists have promised that gene therapy will be the next big leap for medicine. It's a term that's tossed about regularly, but what is it exactly? Trace shows us how scientists can change your very genetic code.

Read More:

How does gene therapy work?http://ghr.nlm.nih.gov/handbook/thera..."Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein."

Gene therapy trial 'cures children'http://www.bbc.co.uk/news/health-2326..."A disease which robs children of the ability to walk and talk has been cured by pioneering gene therapy to correct errors in their DNA, say doctors."

Gene therapy cures diabetic dogshttp://www.newscientist.com/article/d..."Five diabetic beagles no longer needed insulin injections after being given two extra genes, with two of them still alive more than four years later."

Gene Therapy for Cancer: Questions and Answershttp://www.cancer.gov/cancertopics/fa..."Gene therapy is an experimental treatment that involves introducing genetic material into a person's cells to fight or prevent disease."

How does gene therapy work?http://www.scientificamerican.com/art..."Gene therapy is the addition of new genes to a patient's cells to replace missing or malfunctioning genes. Researchers typically do this using a virus to carry the genetic cargo into cells, because that's what viruses evolved to do with their own genetic material."

Gene therapy cures leukaemia in eight dayshttp://www.newscientist.com/article/m...eight-days.htmlWITHIN just eight days of starting a novel gene therapy, David Aponte's "incurable" leukaemia had vanished. For four other patients, the same happened within eight weeks, although one later died from a blood clot unrelated to the treatment, and another after relapsing.

Cell Therapy Shows Promise for Acute Type of Leukemiahttp://www.nytimes.com/2013/03/21/hea..."A treatment that genetically alters a patient's own immune cells to fight cancer has, for the first time, produced remissions in adults with an acute leukemia that is usually lethal, researchers are reporting."

Watch More:Tricking the Immune Systemhttp://www.youtube.com/watch?v=Kr_HRl...Babies with 3 Parents?!http://www.youtube.com/watch?v=jQxsW_...Pick Your Poison: Cyanidehttp://www.youtube.com/watch?v=JDBrdE...____________________

DNews is dedicated to satisfying your curiosity and to bringing you mind-bending stories & perspectives you won't find anywhere else! New videos twice daily.

Watch More DNews on TestTube http://testtube.com/dnews

Subscribe now! http://www.youtube.com/subscription_c...

DNews on Twitter http://twitter.com/dnews

Anthony Carboni on Twitter http://twitter.com/acarboni

Laci Green on Twitter http://twitter.com/gogreen18

Trace Dominguez on Twitter http://twitter.com/trace501

DNews on Facebook http://facebook.com/dnews

DNews on Google+ http://gplus.to/dnews

Discovery News http://discoverynews.com

Continue reading here:
How Does Gene Therapy Work? - YouTube

Posted in Gene therapy | Comments Off on How Does Gene Therapy Work? – YouTube

Epigenetics 1st Edition – amazon.com

Posted: September 17, 2018 at 7:44 pm

The historical accounts of the rise of epigenetics as a field of study, combined with the inclusion of cutting-edging epigenetics research in various biological processes and model organisms, provide the reader with a clear sense of what epigenetics research is about, where it came from, where it is now, and where it is headed. It will prove to be the book that everyone with an interest in epigenetics would want to have and read. Cell; As a whole, Epigenetics is an impressive volume. The contributors provide an accurate survey of the field, from where it began, through where it is today, to where it is heading. Their accounts help set the stage for deepening our understanding of epigenetic phenomena and mechanisms. And the volume will undoubtedly prove to be very useful for students and researchers alike. --Science;Overall, Epigenetics is a scholarly work, eminently readable and a welcome resource for anyone looking for an introduction to this new and vibrant field.--BioEssays; Beautifully illustrated, this book is a rich source of information for a diverse pool of readers, ranging from graduate students making their first steps in a new field of knowledge to more experienced scientists whose research has led them to unfamiliar grounds. What makes; Epigenetics; a truly remarkable and, I believe, a long-lasting achievement is the clear and accessible overview of the major concepts and mechanisms that lay in the foundation of contemporary chromatin research. New details of how specific enzymes and proteins shape chromatin structure and composition may emerge, but the general principles that define how chromatin impacts on many cellular processes are likely to hold true; Genetical Research;In addition to the cutting-edge epigenetic research that is highlighted in this book by eminent scientists in the field, the summaries at the beginning of each chapter, and the multiple tables and colourful illustrations used throughout the book will prove useful in guiding the reader through a discussion of complex biological processes. Undoubtedly, some of these illustrations will be widely used by students and teacher of epigenetics. It is evident that the importance of epigenetics has become widely recognized and this book will be an excellent read for beginners as well as experts in this field; --Nature Cell Biology; What is epigenetics? Asking that question will likely return a number of answers that are all some variation of 'heredity that is not due to changes in DNA sequence.' In other words, epigenetics is not genetics. That seems a definition as indistinct as U.S. Supreme Court Justice Potter Stewart's statement, 'I know it when I see it,' about obscenity. The recent volume, Epigenetics, provides well-needed clarity by setting down the fundamental concepts and principles of this emerging science... With the publication of Epigenetics, this fascinating scientific field no longer needs to be defined by what it is not. --The Quarterly Review of Biology

More here:
Epigenetics 1st Edition - amazon.com

Posted in Epigenetics | Comments Off on Epigenetics 1st Edition – amazon.com